Last reviewed 2026-05-31 · How we verify

BTG-002814

Boston Scientific Corporation · Phase 1 active Small molecule ✓ Verified May 2026

BTG-002814 is a Small molecule drug developed by Boston Scientific Corporation. It is currently in Phase 1 development. Also known as: vandetanib-eluting radiopaque beads.

BTG-002814 is a small molecule intervention being studied in clinical trials for the treatment of Carcinoma, Hepatocellular and Metastatic Colorectal Cancer. The mechanism of action of BTG-002814 is currently unknown.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	BTG-002814
Also known as	vandetanib-eluting radiopaque beads
Sponsor	Boston Scientific Corporation
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Vandetanib-eluting Radiopaque Embolic Beads in Patients With Resectable Liver Malignancies (EARLY_PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

BTG-002814 CI brief — competitive landscape report
BTG-002814 updates RSS · CI watch RSS
Boston Scientific Corporation portfolio CI

Frequently asked questions about BTG-002814

What is BTG-002814?

BTG-002814 is a Small molecule drug developed by Boston Scientific Corporation.

Who makes BTG-002814?

BTG-002814 is developed by Boston Scientific Corporation (see full Boston Scientific Corporation pipeline at /company/boston-scientific-corporation).

Is BTG-002814 also known as anything else?

BTG-002814 is also known as vandetanib-eluting radiopaque beads.

What development phase is BTG-002814 in?

BTG-002814 is in Phase 1.

Manufacturer: Boston Scientific Corporation — full pipeline
Also known as: vandetanib-eluting radiopaque beads

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing